Identification

Name
Saquinavir
Accession Number
DB01232  (APRD00623)
Type
Small Molecule
Groups
Approved, Investigational
Description

An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases. [PubChem]

Structure
Thumb
Synonyms
  • Saquinavir Mesylate
  • SQV
External IDs
RO 31-8959/000 / RO-31-8959/000 / SCH-52852
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fortovase RocheCapsule200 mgOralHoffmann La Roche1998-11-262007-03-06Canada
InviraseCapsule200 mg/1OralGenentech, Inc.1995-12-06Not applicableUs
InviraseCapsule200 mg/1OralRemedy Repack2013-05-012016-10-13Us
InviraseTablet500 mgOralHoffmann La Roche2006-04-10Not applicableCanada
InviraseTablet, film coated500 mgOralRoche Registration Limited1996-10-04Not applicableEu
InviraseTablet, film coated500 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
InviraseTablet, film coated500 mg/1OralGenentech, Inc.2004-12-17Not applicableUs
InviraseCapsule200 mgOralRoche Registration Limited1996-10-04Not applicableEu
Invirase - Cap 200mgCapsule200 mgOralHoffmann La Roche1996-12-31Not applicableCanada
International/Other Brands
Fortovase / ROC
Categories
UNII
L3JE09KZ2F
CAS number
127779-20-8
Weight
Average: 670.8408
Monoisotopic: 670.38426874
Chemical Formula
C38H50N6O5
InChI Key
QWAXKHKRTORLEM-UGJKXSETSA-N
InChI
InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1
IUPAC Name
(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butyl-C-hydroxycarbonimidoyl)-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinolin-2-ylformamido)butanediimidic acid
SMILES
[H][[email protected]@](O)(CN1C[[email protected]@]2([H])CCCC[[email protected]@]2([H])C[[email protected]@]1([H])C(O)=NC(C)(C)C)[[email protected]]([H])(CC1=CC=CC=C1)N=C(O)[[email protected]]([H])(CC(O)=N)NC(=O)C1=NC2=CC=CC=C2C=C1

Pharmacology

Indication

For the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.

Structured Indications
Pharmacodynamics

Saquinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Saquinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

Mechanism of action

Saquinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.

TargetActionsOrganism
AHuman immunodeficiency virus type 1 protease
inhibitor
Human immunodeficiency virus 1
Absorption

Absolute bioavailability averages 4%

Volume of distribution
  • 700 L
Protein binding

98%

Metabolism

Hepatic

Route of elimination

In vitro studies using human liver microsomes have shown that the metabolism of saquinavir is cytochrome P450 mediated with the specific isoenzyme, CYP3A4, responsible for more than 90% of the hepatic metabolism. Only 1% of saquinavir is excreted in the urine, so the impact of renal impairment on saquinavir elimination should be minimal.

Half life
Not Available
Clearance
  • 1.14 L/h/kg [Healthy volunteers receiving IV doses of 6, 36, and 72 mg]
Toxicity

Probably experience pain in the throat

Affected organisms
  • Human Immunodeficiency Virus
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Saquinavir.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Saquinavir.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Saquinavir.Investigational
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Saquinavir.Experimental, Illicit
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Saquinavir.Approved, Investigational
AbirateroneThe serum concentration of Saquinavir can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Saquinavir.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Saquinavir.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Saquinavir.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Saquinavir.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Saquinavir.Investigational, Withdrawn
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Saquinavir.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Saquinavir.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Saquinavir.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Saquinavir.Experimental, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Saquinavir.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Saquinavir.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Saquinavir.Experimental, Investigational
AlectinibThe serum concentration of Saquinavir can be increased when it is combined with Alectinib.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Saquinavir.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Saquinavir.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Saquinavir.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Saquinavir.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Saquinavir.Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Saquinavir.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Saquinavir.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Saquinavir.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Saquinavir.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Saquinavir.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Saquinavir.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Saquinavir.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Saquinavir.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Saquinavir.Experimental, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Saquinavir.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Saquinavir.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of Saquinavir can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Saquinavir.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Saquinavir.Approved
AmiodaroneSaquinavir may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Saquinavir.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Saquinavir.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Saquinavir.Approved, Investigational
AmoxapineAmoxapine may increase the QTc-prolonging activities of Saquinavir.Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Saquinavir.Approved
AmsacrineThe serum concentration of Saquinavir can be increased when it is combined with Amsacrine.Approved
AnagrelideSaquinavir may increase the QTc-prolonging activities of Anagrelide.Approved
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Saquinavir.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Saquinavir.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Saquinavir.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Saquinavir.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Saquinavir.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ApremilastThe metabolism of Apremilast can be decreased when combined with Saquinavir.Approved, Investigational
AprepitantThe serum concentration of Saquinavir can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Saquinavir.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Saquinavir.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Saquinavir.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Saquinavir.Approved
AsenapineThe serum concentration of Saquinavir can be increased when it is combined with Asenapine.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Saquinavir.Approved, Withdrawn
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Saquinavir.Investigational
AtazanavirThe metabolism of Saquinavir can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Saquinavir.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Saquinavir.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Saquinavir.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Saquinavir.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Saquinavir.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Saquinavir.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Saquinavir.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Saquinavir.Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Saquinavir.Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Saquinavir.Approved
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Saquinavir.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Saquinavir.Approved
BelinostatThe serum concentration of Belinostat can be decreased when it is combined with Saquinavir.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Saquinavir.Investigational
BenzocaineThe serum concentration of Saquinavir can be increased when it is combined with Benzocaine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Saquinavir.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Saquinavir.Approved
BepridilBepridil may increase the arrhythmogenic activities of Saquinavir.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Saquinavir.Approved, Vet Approved
BetaxololThe metabolism of Saquinavir can be decreased when combined with Betaxolol.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Saquinavir.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Saquinavir.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Saquinavir.Approved
BiperidenThe serum concentration of Saquinavir can be increased when it is combined with Biperiden.Approved, Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Saquinavir.Approved
BoceprevirThe serum concentration of Saquinavir can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Saquinavir.Approved, Investigational
BosentanThe serum concentration of Saquinavir can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Saquinavir.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Saquinavir.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Saquinavir.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Saquinavir.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Saquinavir.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Saquinavir.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Saquinavir.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Saquinavir.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Saquinavir.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Saquinavir.Investigational, Withdrawn
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Saquinavir.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Saquinavir.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Saquinavir.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Saquinavir.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Saquinavir.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Saquinavir.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Saquinavir.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Saquinavir.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Saquinavir.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Saquinavir.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Saquinavir.Approved, Nutraceutical
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Saquinavir.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Saquinavir.Approved
Candesartan cilexetilThe serum concentration of Saquinavir can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Saquinavir can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Saquinavir can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Saquinavir.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Saquinavir.Experimental
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Saquinavir.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Saquinavir.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Saquinavir.Approved, Investigational
CaspofunginThe serum concentration of Saquinavir can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Saquinavir.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Saquinavir.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Saquinavir.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Saquinavir.Approved, Vet Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Saquinavir.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Saquinavir.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Saquinavir.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Saquinavir.Approved, Illicit
ChloroquineChloroquine may increase the QTc-prolonging activities of Saquinavir.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Saquinavir.Investigational, Withdrawn
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Saquinavir.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Saquinavir.Approved, Vet Approved
ChlorpropamideThe serum concentration of Saquinavir can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Saquinavir can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Saquinavir.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Saquinavir.Approved, Nutraceutical
CholesterolThe serum concentration of Saquinavir can be increased when it is combined with Cholesterol.Experimental, Investigational
Cholic AcidThe serum concentration of Saquinavir can be decreased when it is combined with Cholic Acid.Approved
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Saquinavir.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Saquinavir.Experimental
CilazaprilThe serum concentration of Saquinavir can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Saquinavir.Approved
CimetidineThe serum concentration of Saquinavir can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Saquinavir.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Saquinavir.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Saquinavir.Approved
CitalopramThe metabolism of Citalopram can be decreased when combined with Saquinavir.Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Saquinavir.Approved
ClemastineThe metabolism of Saquinavir can be decreased when combined with Clemastine.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Saquinavir.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Saquinavir.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Saquinavir.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Saquinavir.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Saquinavir.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Saquinavir.Approved
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Saquinavir.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Saquinavir.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Saquinavir.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Saquinavir.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Saquinavir.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Saquinavir.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Saquinavir.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Saquinavir.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Saquinavir.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Saquinavir.Approved, Illicit
ClotrimazoleThe metabolism of Saquinavir can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Saquinavir.Approved
CobicistatThe serum concentration of Saquinavir can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Saquinavir.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Saquinavir.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Saquinavir.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Saquinavir.Approved
ColforsinThe serum concentration of Saquinavir can be increased when it is combined with Colforsin.Experimental, Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Saquinavir.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Saquinavir.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Saquinavir.Approved
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Saquinavir.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Saquinavir.Experimental
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Saquinavir.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Saquinavir.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Saquinavir.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Saquinavir is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Saquinavir.Approved, Investigational, Vet Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Saquinavir.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Saquinavir.Approved
DabrafenibThe serum concentration of Saquinavir can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Saquinavir.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Saquinavir.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Saquinavir.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Saquinavir.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Saquinavir.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Saquinavir.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Saquinavir.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Saquinavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Saquinavir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Saquinavir.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Saquinavir.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Saquinavir.Approved, Investigational
DeferasiroxThe serum concentration of Saquinavir can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Saquinavir.Approved
DegarelixDegarelix may increase the QTc-prolonging activities of Saquinavir.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Saquinavir.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Saquinavir.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Saquinavir.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Saquinavir.Approved
DesloratadineThe serum concentration of Saquinavir can be increased when it is combined with Desloratadine.Approved, Investigational
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Saquinavir.Approved
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Saquinavir.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Saquinavir.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Saquinavir.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Saquinavir.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Saquinavir.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Saquinavir.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Saquinavir.Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Saquinavir.Approved
DexlansoprazoleThe serum concentration of Saquinavir can be increased when it is combined with Dexlansoprazole.Approved
DexrabeprazoleThe serum concentration of Saquinavir can be increased when it is combined with Dexrabeprazole.Experimental
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Saquinavir.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Saquinavir.Approved, Illicit, Investigational, Withdrawn
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Saquinavir.Approved, Illicit, Vet Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Saquinavir.Experimental
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Saquinavir.Approved, Vet Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Saquinavir.Approved, Investigational
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Saquinavir.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Saquinavir.Approved, Investigational
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Saquinavir.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Saquinavir.Approved, Investigational
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Saquinavir.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Saquinavir.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Saquinavir.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Saquinavir.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Saquinavir.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Saquinavir.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Saquinavir.Experimental
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Saquinavir.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Saquinavir.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Saquinavir.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Saquinavir.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Saquinavir.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Saquinavir.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Saquinavir.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Saquinavir.Approved, Investigational
DofetilideSaquinavir may increase the arrhythmogenic activities of Dofetilide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Saquinavir.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Saquinavir.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Saquinavir.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Saquinavir.Approved
DosulepinThe metabolism of Saquinavir can be decreased when combined with Dosulepin.Approved
DoxazosinThe serum concentration of Saquinavir can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Saquinavir can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Saquinavir.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Saquinavir.Approved, Investigational
DoxycyclineThe metabolism of Saquinavir can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Saquinavir.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Saquinavir.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Saquinavir.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Saquinavir.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Saquinavir.Approved
DuloxetineThe metabolism of Saquinavir can be decreased when combined with Duloxetine.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Saquinavir.Approved, Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Saquinavir.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Saquinavir.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Saquinavir is combined with Efavirenz.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Saquinavir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Saquinavir.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Saquinavir.Approved
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Saquinavir.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Saquinavir.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Saquinavir.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Saquinavir.Approved, Vet Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Saquinavir.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Saquinavir.Approved, Investigational
EnzalutamideThe serum concentration of Saquinavir can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Saquinavir can be increased when it is combined with Epinastine.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Saquinavir.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Saquinavir.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Saquinavir.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Saquinavir.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Saquinavir.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Saquinavir.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Saquinavir.Approved
EribulinEribulin may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Saquinavir.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Saquinavir.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Saquinavir.Approved, Investigational
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Saquinavir.Investigational
EsomeprazoleThe serum concentration of Saquinavir can be increased when it is combined with Esomeprazole.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Saquinavir.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Saquinavir.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Saquinavir.Approved, Investigational
EstramustineThe metabolism of Estramustine can be decreased when combined with Saquinavir.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Saquinavir.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Saquinavir.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Saquinavir.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Saquinavir.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Saquinavir.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Saquinavir.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Saquinavir.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Saquinavir.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Saquinavir.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Saquinavir.Approved
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Saquinavir.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Saquinavir.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Saquinavir.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Saquinavir.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Saquinavir.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Saquinavir.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Saquinavir.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Saquinavir.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Saquinavir.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Saquinavir.Approved
FamotidineThe serum concentration of Saquinavir can be increased when it is combined with Famotidine.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Saquinavir.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Saquinavir.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Saquinavir.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Saquinavir.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Saquinavir.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Saquinavir.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Saquinavir.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Saquinavir.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Saquinavir.Approved, Investigational
FlecainideSaquinavir may increase the arrhythmogenic activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Saquinavir.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Saquinavir.Investigational
FluconazoleFluconazole may increase the QTc-prolonging activities of Saquinavir.Approved
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Saquinavir.Approved
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Saquinavir.Approved, Vet Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Saquinavir.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Saquinavir.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Saquinavir.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Saquinavir.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Saquinavir.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Saquinavir.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Saquinavir.Approved, Vet Approved
FlupentixolThe serum concentration of Saquinavir can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Saquinavir can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Saquinavir.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Saquinavir.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Saquinavir.Approved
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Saquinavir.Approved, Illicit
FlutamideThe metabolism of Flutamide can be decreased when combined with Saquinavir.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Saquinavir.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Saquinavir.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Saquinavir.Approved
FluvoxamineThe metabolism of Saquinavir can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Saquinavir.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Saquinavir.Approved
FosaprepitantThe serum concentration of Saquinavir can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Saquinavir.Approved
FosphenytoinThe metabolism of Saquinavir can be increased when combined with Fosphenytoin.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Saquinavir.Approved, Investigational
Fusidic AcidThe serum concentration of Fusidic Acid can be increased when it is combined with Saquinavir.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Saquinavir.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Saquinavir.Approved
GarlicThe serum concentration of Saquinavir can be decreased when it is combined with Garlic.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Saquinavir.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Saquinavir.Approved
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Saquinavir.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
GenisteinThe serum concentration of Saquinavir can be increased when it is combined with Genistein.Investigational
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Saquinavir.Approved, Investigational
GlecaprevirThe serum concentration of Glecaprevir can be decreased when it is combined with Saquinavir.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Saquinavir.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Saquinavir.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Saquinavir.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Saquinavir.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Saquinavir.Approved, Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Saquinavir.Approved
GlycerinThe serum concentration of Saquinavir can be increased when it is combined with Glycerin.Approved, Investigational
GoserelinGoserelin may increase the QTc-prolonging activities of Saquinavir.Approved
Gramicidin DThe serum concentration of Saquinavir can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Saquinavir.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Saquinavir.Investigational, Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Saquinavir.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Saquinavir.Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Saquinavir.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Saquinavir.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Saquinavir.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Saquinavir.Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Saquinavir.Withdrawn
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Saquinavir.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Saquinavir.Approved, Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Saquinavir.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Saquinavir.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Saquinavir.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Saquinavir.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Saquinavir.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Saquinavir.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Saquinavir.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Saquinavir.Approved
IbutilideSaquinavir may increase the QTc-prolonging activities of Ibutilide.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Saquinavir.Approved, Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Saquinavir resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Saquinavir.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Saquinavir.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Saquinavir.Approved, Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Saquinavir.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Saquinavir.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Saquinavir.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Saquinavir.Approved
IndinavirThe metabolism of Saquinavir can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Saquinavir.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Saquinavir.Approved
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Saquinavir.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Saquinavir.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Saquinavir.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Saquinavir.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Saquinavir.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Saquinavir.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Saquinavir.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Saquinavir.Approved
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Saquinavir.Experimental
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Saquinavir.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Saquinavir.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Saquinavir.Approved, Vet Approved
IsoniazidThe metabolism of Saquinavir can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Saquinavir.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Saquinavir.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Saquinavir.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Saquinavir.Investigational
ItraconazoleThe serum concentration of Saquinavir can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Saquinavir.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Saquinavir.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Saquinavir.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Saquinavir.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Saquinavir.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Saquinavir.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Saquinavir.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Saquinavir.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Saquinavir.Approved, Investigational
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Saquinavir.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Saquinavir.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Saquinavir.Approved, Investigational
LansoprazoleThe serum concentration of Saquinavir can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Saquinavir.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Saquinavir.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Saquinavir.Approved
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Saquinavir.Approved
LenvatinibSaquinavir may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Saquinavir.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Saquinavir.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Saquinavir.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Saquinavir.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Saquinavir.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Saquinavir.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Saquinavir.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Saquinavir.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Saquinavir.Approved
LidocaineSaquinavir may increase the arrhythmogenic activities of Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Saquinavir.Approved
LiothyronineThe serum concentration of Saquinavir can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Saquinavir can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Saquinavir.Approved
LisinoprilThe serum concentration of Saquinavir can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Saquinavir.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Saquinavir.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Saquinavir.Experimental
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Saquinavir.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Saquinavir.Approved
LopinavirSaquinavir may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Saquinavir.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Saquinavir.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Saquinavir.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Saquinavir.Approved, Investigational
LuliconazoleThe serum concentration of Saquinavir can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Saquinavir can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Saquinavir.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Saquinavir.Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Saquinavir.Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Saquinavir.Illicit, Investigational, Withdrawn
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Saquinavir.Approved
ManidipineThe metabolism of Saquinavir can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Saquinavir.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Saquinavir.Approved
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Saquinavir.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Saquinavir.Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Saquinavir.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Saquinavir.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Saquinavir.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Saquinavir.Approved
Megestrol acetateThe serum concentration of Saquinavir can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Saquinavir.Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Saquinavir.Approved, Vet Approved
MeprobamateThe serum concentration of Saquinavir can be increased when it is combined with Meprobamate.Approved, Illicit
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Saquinavir.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Saquinavir.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Saquinavir.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Saquinavir.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Saquinavir.Experimental
MethanthelineThe serum concentration of Saquinavir can be increased when it is combined with Methantheline.Approved, Investigational
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Saquinavir.Illicit, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Saquinavir.Approved
MethotrimeprazineThe metabolism of Saquinavir can be decreased when combined with Methotrimeprazine.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Saquinavir.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Saquinavir.Approved, Investigational, Vet Approved
Methyl salicylateThe metabolism of Methyl salicylate can be decreased when combined with Saquinavir.Approved, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Saquinavir.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Saquinavir.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Saquinavir.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Saquinavir.Approved
MetiamideThe serum concentration of Saquinavir can be increased when it is combined with Metiamide.Experimental
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Saquinavir.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Saquinavir.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Saquinavir.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Saquinavir.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Saquinavir.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Saquinavir.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Saquinavir.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Saquinavir.Approved, Illicit
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Saquinavir.Approved
MifepristoneThe serum concentration of Saquinavir can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Saquinavir.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Saquinavir.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Saquinavir.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Saquinavir.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Saquinavir.Approved, Investigational
MitomycinThe serum concentration of Saquinavir can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Saquinavir can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Saquinavir.Approved, Investigational
ModafinilThe metabolism of Modafinil can be decreased when combined with Saquinavir.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Saquinavir.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Saquinavir.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Saquinavir.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Saquinavir.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Saquinavir.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Saquinavir.Approved, Vet Approved
NaltrexoneThe serum concentration of Saquinavir can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Saquinavir can be increased when it is combined with Naringenin.Experimental
NateglinideThe metabolism of Nateglinide can be decreased when combined with Saquinavir.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Saquinavir.Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Saquinavir.Approved, Withdrawn
NelfinavirThe metabolism of Saquinavir can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Saquinavir can be increased when it is combined with Neostigmine.Approved, Vet Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Saquinavir.Approved, Investigational
NetupitantThe serum concentration of Saquinavir can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Saquinavir can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Saquinavir.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Saquinavir.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Saquinavir.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Saquinavir.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Saquinavir.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Saquinavir.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Saquinavir.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Saquinavir.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Saquinavir.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Saquinavir.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Saquinavir.Approved, Investigational
NizatidineThe serum concentration of Saquinavir can be increased when it is combined with Nizatidine.Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Saquinavir.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Saquinavir.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Saquinavir.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Saquinavir.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Saquinavir.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Saquinavir.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Saquinavir.Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Saquinavir.Approved
OlanzapineThe serum concentration of Saquinavir can be increased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Saquinavir.Approved
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Saquinavir.Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Saquinavir.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Saquinavir.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Saquinavir.Approved
OmeprazoleThe serum concentration of Saquinavir can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Saquinavir.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Saquinavir.Investigational
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Saquinavir.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Saquinavir.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Saquinavir.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Saquinavir.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Saquinavir is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Saquinavir.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Saquinavir.Approved, Vet Approved
P-NitrophenolThe serum concentration of Saquinavir can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Saquinavir.Approved, Vet Approved
PaliperidoneSaquinavir may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Saquinavir can be increased when it is combined with Palmitic Acid.Approved, Experimental
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Saquinavir.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Saquinavir.Approved, Investigational
PantoprazoleThe serum concentration of Saquinavir can be increased when it is combined with Pantoprazole.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Saquinavir.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Saquinavir.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Saquinavir.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Saquinavir.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Saquinavir.Approved
ParoxetineThe metabolism of Saquinavir can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Saquinavir.Approved
Peginterferon alfa-2bThe serum concentration of Saquinavir can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Saquinavir.Approved
PentobarbitalThe metabolism of Saquinavir can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Saquinavir.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Saquinavir.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Saquinavir.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Saquinavir.Approved, Investigational
PerindoprilThe serum concentration of Saquinavir can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Saquinavir.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Saquinavir.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Saquinavir.Approved
PethidineThe risk or severity of adverse effects can be increased when Saquinavir is combined with Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Saquinavir.Withdrawn
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Saquinavir.Approved, Investigational, Withdrawn
PhenobarbitalThe metabolism of Saquinavir can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Saquinavir.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Saquinavir.Approved, Investigational
PhenytoinThe metabolism of Saquinavir can be increased when combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be decreased when it is combined with Saquinavir.Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Saquinavir.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Saquinavir.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Saquinavir.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Saquinavir.Withdrawn
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Saquinavir.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Saquinavir.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Saquinavir.Approved
Platelet Activating FactorThe serum concentration of Saquinavir can be decreased when it is combined with Platelet Activating Factor.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Saquinavir.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Saquinavir.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Saquinavir.Approved
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Saquinavir.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Saquinavir.Approved, Investigational
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Saquinavir.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Saquinavir.Approved, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Saquinavir.Investigational
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Saquinavir resulting in a loss in efficacy.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Saquinavir.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Saquinavir.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Saquinavir.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Saquinavir.Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Saquinavir.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Saquinavir.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Saquinavir.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Saquinavir.Experimental, Investigational
PrimaquinePrimaquine may increase the QTc-prolonging activities of Saquinavir.Approved
PrimidoneThe metabolism of Saquinavir can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Saquinavir can be increased when it is combined with Probenecid.Approved
ProcainamideSaquinavir may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Saquinavir.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Saquinavir.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Saquinavir.Approved
PromazinePromazine may increase the QTc-prolonging activities of Saquinavir.Approved, Vet Approved
PromethazineThe serum concentration of Saquinavir can be increased when it is combined with Promethazine.Approved
PropafenoneSaquinavir may increase the arrhythmogenic activities of Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Saquinavir.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe metabolism of Propoxyphene napsylate can be decreased when combined with Saquinavir.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Saquinavir.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Saquinavir.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Saquinavir.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Saquinavir.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Saquinavir.Approved, Illicit
QuercetinThe serum concentration of Saquinavir can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Saquinavir.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Saquinavir.Approved, Investigational
QuinidineSaquinavir may increase the QTc-prolonging activities of Quinidine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Saquinavir.Approved
RabeprazoleThe serum concentration of Saquinavir can be increased when it is combined with Rabeprazole.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Saquinavir.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Saquinavir.Approved, Investigational
RanitidineThe serum concentration of Saquinavir can be increased when it is combined with Ranitidine.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Saquinavir.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Saquinavir.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Saquinavir.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Saquinavir.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Saquinavir.Approved
RifabutinThe serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Saquinavir.Approved
RifampicinThe risk or severity of adverse effects can be increased when Rifampicin is combined with Saquinavir.Approved
RifapentineThe metabolism of Saquinavir can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Saquinavir.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Saquinavir.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Saquinavir.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Saquinavir.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Saquinavir.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Saquinavir.Approved, Investigational
RitonavirThe metabolism of Saquinavir can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Saquinavir.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Saquinavir.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Saquinavir.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Saquinavir.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Saquinavir.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Saquinavir.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Saquinavir.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Saquinavir.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Saquinavir.Approved
Roxatidine acetateThe serum concentration of Saquinavir can be increased when it is combined with Roxatidine acetate.Approved, Investigational
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Saquinavir.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Saquinavir.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Saquinavir.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Saquinavir.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Saquinavir.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Saquinavir.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Saquinavir.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Saquinavir.Approved
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Saquinavir.Approved
ScopolamineThe serum concentration of Saquinavir can be increased when it is combined with Scopolamine.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Saquinavir.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Saquinavir.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Saquinavir.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Saquinavir.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Saquinavir.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Saquinavir.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Saquinavir.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Saquinavir.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Saquinavir.Approved
SiltuximabThe serum concentration of Saquinavir can be decreased when it is combined with Siltuximab.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Saquinavir.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Saquinavir.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Saquinavir.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Saquinavir.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Saquinavir.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Saquinavir.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Saquinavir.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Saquinavir.Investigational
SotalolSaquinavir may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Saquinavir.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Saquinavir.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Saquinavir.Approved
SpironolactoneThe serum concentration of Saquinavir can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Saquinavir can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StaurosporineThe serum concentration of Saquinavir can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Saquinavir can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Saquinavir can be decreased when it is combined with Streptozocin.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Saquinavir.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Saquinavir.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Saquinavir.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Saquinavir.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Saquinavir.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Saquinavir.Approved, Investigational
SumatriptanThe serum concentration of Saquinavir can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Saquinavir.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Saquinavir.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Saquinavir.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Saquinavir.Approved
TacrineThe serum concentration of Saquinavir can be increased when it is combined with Tacrine.Investigational, Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Saquinavir.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Saquinavir.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Saquinavir.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Saquinavir.Approved, Investigational
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Saquinavir.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Saquinavir.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Saquinavir.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Saquinavir.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Saquinavir.Approved
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Saquinavir.Approved, Withdrawn
TelavancinSaquinavir may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Saquinavir.Approved
TelmisartanThe serum concentration of Saquinavir can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Saquinavir.Approved
TemsirolimusThe risk or severity of adverse effects can be increased when Saquinavir is combined with Temsirolimus.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Saquinavir.Approved
TerazosinThe serum concentration of Saquinavir can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Saquinavir.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Saquinavir.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Saquinavir.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Saquinavir.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Saquinavir.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Saquinavir.Approved, Investigational
TetrabenazineSaquinavir may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Saquinavir.Approved, Vet Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Saquinavir.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Saquinavir.Approved, Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Saquinavir.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Saquinavir.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Saquinavir.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Saquinavir.Approved, Investigational
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Saquinavir resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Saquinavir.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Saquinavir.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Saquinavir.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Saquinavir.Approved
TipranavirThe serum concentration of Saquinavir can be decreased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Saquinavir.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Saquinavir.Approved
TocilizumabThe serum concentration of Saquinavir can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Saquinavir.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Saquinavir.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Saquinavir.Approved
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Saquinavir.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Saquinavir.Approved
ToremifeneThe risk or severity of adverse effects can be increased when Saquinavir is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Saquinavir.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Saquinavir.Approved, Investigational
TranylcypromineThe metabolism of Saquinavir can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Saquinavir.Approved
TrazodoneSaquinavir may increase the QTc-prolonging activities of Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Saquinavir.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Saquinavir.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Saquinavir.Approved
TrifluoperazineThe serum concentration of Saquinavir can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Saquinavir can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Saquinavir.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Saquinavir.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Saquinavir.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Saquinavir.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Saquinavir.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Saquinavir.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Saquinavir.Approved, Experimental
UdenafilThe metabolism of Udenafil can be decreased when combined with Saquinavir.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Saquinavir.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Saquinavir.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Saquinavir.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Saquinavir.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Saquinavir.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Saquinavir.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Saquinavir.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Saquinavir.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Saquinavir.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Saquinavir.Approved
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Saquinavir.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Saquinavir.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Saquinavir.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Saquinavir.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Saquinavir.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Saquinavir.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Saquinavir.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Saquinavir.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Saquinavir.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Saquinavir.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Saquinavir.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Saquinavir.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Saquinavir.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Saquinavir.Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Saquinavir.Approved, Investigational
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Saquinavir.Approved
VoriconazoleThe metabolism of Saquinavir can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Saquinavir.Approved
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Saquinavir.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Saquinavir.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Saquinavir.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Saquinavir.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Saquinavir.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Saquinavir.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Saquinavir.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Saquinavir.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Saquinavir can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Saquinavir.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Saquinavir.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Saquinavir.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Saquinavir.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Saquinavir.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Saquinavir.Approved, Investigational
Food Interactions
  • Take after a full meal.

References

Synthesis Reference
US5196438
General References
  1. Forestier F, de Renty P, Peytavin G, Dohin E, Farinotti R, Mandelbrot L: Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am J Obstet Gynecol. 2001 Jul;185(1):178-81. [PubMed:11483925]
External Links
KEGG Drug
D00429
PubChem Compound
441243
PubChem Substance
46508726
ChemSpider
390016
BindingDB
519
ChEBI
63621
ChEMBL
CHEMBL114
Therapeutic Targets Database
DAP000171
PharmGKB
PA451305
HET
ROC
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Saquinavir
ATC Codes
J05AE01 — Saquinavir
AHFS Codes
  • 08:18.08.08 — HIV Protease Inhibitors
PDB Entries
1c6z / 1fb7 / 1hxb / 2nmy / 2nmz / 2nnk / 2nnp / 3cyx / 3d1x / 3d1y
show 17 more
FDA label
Download (362 KB)
MSDS
Download (15.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Unknown StatusTreatmentPulmonary Arterial Hypertension (PAH)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections10
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pregnancy1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections22
2CompletedTreatmentIDV Associated Nephrotoxicity1
2CompletedTreatmentSarcomas1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2WithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2, 3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
3CompletedNot AvailableDirectly Observed Therapy / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentAIDS-Associated Nephropathy / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections10
4CompletedDiagnosticCardiovascular Disease (CVD) / HIV-Associated Lipodystrophy Syndrome1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHealthy Volunteers / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections5
Not AvailableCompletedPreventionIschemia, Cerebral1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections4

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral200 mg/1
TabletOral500 mg
Tablet, film coatedOral500 mg/1
Tablet, film coatedOral500 mg
CapsuleOral200 mg
Prices
Unit descriptionCostUnit
Invirase 500 mg tablet8.72USD tablet
Invirase 200 mg capsule3.87USD capsule
Fortovase 200 mg capsule1.46USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5196438No1993-11-192010-11-19Us
CA2224125No2004-09-282016-06-04Canada
CA2030433No1997-10-212010-11-21Canada
US6352717Yes2000-05-162020-05-16Us
US6008228Yes1995-12-062015-12-06Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)349.84 °CNot Available
water solubilityInsolubleNot Available
logP3.8Not Available
Caco2 permeability-6.26ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00765 mg/mLALOGPS
logP3.96ALOGPS
logP2.58ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)5.11ChemAxon
pKa (Strongest Basic)8.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area174.72 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity198.65 m3·mol-1ChemAxon
Polarizability74.25 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7774
Blood Brain Barrier-0.9949
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.9048
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.5195
Renal organic cation transporterNon-inhibitor0.8612
CYP450 2C9 substrateNon-substrate0.8593
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7406
CYP450 1A2 substrateNon-inhibitor0.8729
CYP450 2C9 inhibitorNon-inhibitor0.7442
CYP450 2D6 inhibitorNon-inhibitor0.8536
CYP450 2C19 inhibitorNon-inhibitor0.7124
CYP450 3A4 inhibitorInhibitor0.5219
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9053
Ames testNon AMES toxic0.8489
CarcinogenicityNon-carcinogens0.865
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6007 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9687
hERG inhibition (predictor II)Inhibitor0.8153
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxamides. These are quinolines in which the quinoline ring system is substituted by one or more carboxamide groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxamides
Direct Parent
Quinoline carboxamides
Alternative Parents
Phenylbutylamines / Amphetamines and derivatives / Pyridinecarboxylic acids and derivatives / Piperidinecarboxamides / 2-heteroaryl carboxamides / Aralkylamines / Heteroaromatic compounds / Trialkylamines / Secondary carboxylic acid amides / Secondary alcohols
show 8 more
Substituents
Quinoline-2-carboxamide / Phenylbutylamine / Amphetamine or derivatives / 2-piperidinecarboxamide / Piperidinecarboxamide / Pyridine carboxylic acid or derivatives / 2-heteroaryl carboxamide / Aralkylamine / Monocyclic benzene moiety / Piperidine
show 26 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
quinolines, L-asparagine derivative (CHEBI:63621)

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
Yes
Actions
Inhibitor
General Function
Aspartic-type endopeptidase activity
Specific Function
Not Available
Gene Name
pol
Uniprot ID
Q72874
Uniprot Name
Pol polyprotein
Molecular Weight
10778.7 Da
References
  1. Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2008 Apr 15;29(5):673-85. [PubMed:17849388]
  2. Dandache S, Sevigny G, Yelle J, Stranix BR, Parkin N, Schapiro JM, Wainberg MA, Wu JJ: In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007 Nov;51(11):4036-43. Epub 2007 Jul 16. [PubMed:17638694]
  3. Dandache S, Coburn CA, Oliveira M, Allison TJ, Holloway MK, Wu JJ, Stranix BR, Panchal C, Wainberg MA, Vacca JP: PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63. doi: 10.1002/jmv.21329. [PubMed:19040279]
  4. Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, Ruane P, Hellinger J, Shirvani V, Zolopa A, Shafer RW: HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother. 2010 Oct;54(10):4253-61. doi: 10.1128/AAC.00574-10. Epub 2010 Jul 26. [PubMed:20660676]
  5. Alcaro S, Artese A, Ceccherini-Silberstein F, Ortuso F, Perno CF, Sing T, Svicher V: Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance. J Chem Inf Model. 2009 Jul;49(7):1751-61. doi: 10.1021/ci900012k. [PubMed:19537723]
  6. Vella S, Lazzarin A, Carosi G, Sinicco A, Armignacco O, Angarano G, Andreoni M, Tambussi G, Chiodera A, Floridia M, Scaccabarozzi S, Facey K, Duncan I, Boudes P, Bragman K: A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection. Antivir Ther. 1996 Aug;1(3):129-40. [PubMed:11322246]
  7. Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH: Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci. 1997 Aug;19(4):159-75. [PubMed:9297727]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name
CYP11A1
Uniprot ID
P05108
Uniprot Name
Cholesterol side-chain cleavage enzyme, mitochondrial
Molecular Weight
60101.87 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, Liang Z, Halifax K, Lindup WE, Back DJ: Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab Dispos. 2001 Mar;29(3):299-303. [PubMed:11181499]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, Liang Z, Halifax K, Lindup WE, Back DJ: Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab Dispos. 2001 Mar;29(3):299-303. [PubMed:11181499]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9. [PubMed:10894301]
  2. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137]
  3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  4. Kim AE, Dintaman JM, Waddell DS, Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45. [PubMed:9732409]
  5. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH: P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 2001 Apr;59(4):806-13. [PubMed:11259625]
  6. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  7. Eagling VA, Profit L, Back DJ: Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol. 1999 Oct;48(4):543-52. [PubMed:10583025]
  8. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26. [PubMed:15180340]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM: Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos. 2000 Mar;28(3):329-34. [PubMed:10681378]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Gupta A, Zhang Y, Unadkat JD, Mao Q: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004 Jul;310(1):334-41. Epub 2004 Mar 8. [PubMed:15007102]
  2. Janneh O, Owen A, Chandler B, Hartkoorn RC, Hart CA, Bray PG, Ward SA, Back DJ, Khoo SH: Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS. 2005 Dec 2;19(18):2097-102. [PubMed:16284458]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. [PubMed:12490595]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Williams GC, Liu A, Knipp G, Sinko PJ: Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother. 2002 Nov;46(11):3456-62. [PubMed:12384350]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Williams GC, Liu A, Knipp G, Sinko PJ: Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother. 2002 Nov;46(11):3456-62. [PubMed:12384350]
  2. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH: Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS. 2002 Nov 22;16(17):2295-301. [PubMed:12441801]
  3. Zelcer N, Huisman MT, Reid G, Wielinga P, Breedveld P, Kuil A, Knipscheer P, Schellens JH, Schinkel AH, Borst P: Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44. Epub 2003 Apr 17. [PubMed:12702717]
  4. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25. [PubMed:15504753]

Drug created on June 13, 2005 07:24 / Updated on November 14, 2017 08:09